ARGX-111

ARGX-111 binds to native MET with an EC₅₀ ranging from 0.1 nmol/L to 0.7 nmol/L, competes with HGF displaying an IC₅₀ of 1.3 nmol/L and an IMAX of 95%^[1].
ARGX-111 inhibits HGF-induced MET autophosphorylation in A549 cells (IC₅₀ = 5.3 nmol/L, IMAX = 74%), inhibits MET autophosphorylation in both MKN-45 cells (IC₅₀ = 0.2 nmol/L, IMAX = 63%) and EBC-1 cells (IC₅₀ = 12.7 nmol/L, IMAX = 69%)^[1].
ARGX-111 neutralizes the promigratory effect of HGF, inhibits HGF-dependent colony formation by 78% in A549 cells^[1].
ARGX-111 (1-10 nM/L) inhibits HGF-induced branched tubule formation in SV40 T-antigen-transformed LOC human kidney epithelial cell spheroids^[1].
ARGX-111 (0.1-100 h) promotes a rapid decrease in MET expression in MKN-45, EBC-1 and MDA-MB 231 cells^[1].
ARGX-111 (24-48 h) does not promote receptor shedding but reduced total MET protein levels in MKN-45 cells^[1].
ARGX-111 (0-1000 nM/L) induces dose-dependent lysis in MKN-45, NCI-H441, A549 cells^[1].
ARGX-111 induces antibody-dependent cellular phagocytosis (ADCP) in MKN-45 and 786-O cells^[1].
ARGX-111 (0-667 nM/L) promotes dose-dependent ADCC in ALDH-1-sorted MDA-MB-231, CRCM168, CRCM174, CRCM389 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.